European Association for the Study of the Liver

Tweet this page
<
2019
2020
2021
2022
2023
>
Registration as it was on 23 Nov 2023
How to read and use this data card.
Download this datacard
The following entries are flagged as duplicates of this organisation: 39568344135-06

Overview

Lobbying Costs

100,000€ - 199,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

2.1 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    European Association for the Study of the Liver   (EASL)

    EU Transparency Register

    597006135119-96 First registered on 13 Jun 2019

    Goals / Remit

    EASL is a medical association dedicated to pursuing excellence in liver research, clinical practice of liver disorders, and in providing education to all those interested in hepatology. While the roots of the association were founded in Europe in 1966, EASL continues to engage globally with all stakeholders in the liver field wherever they are based. Our aim is to spread knowledge and expertise in best practices and the latest scientific breakthroughs in hepatology.

    Main EU files targeted

    EU4Health programme, Europe's beating cancer plan, the ECDC mandate extension regulation, the Farm to Fork Strategy, Digital Health Space, the CoƓuncil recommendation for cancer screening, The Council recommendations for vaccine-preventable cancers, EU legislation on taxation of alcohol, the Proposal for mandatory labelling of the list of ingredients and nutrition declaration on alcoholic beverage products & Proposal for health warnings on alcoholic beverage product.

    Address

    Head Office
    7, rue Daubin
    Geneva 1203
    SWITZERLAND
    EU Office
    7, rue Daubin
    Geneva 1203
    SWITZERLAND

    Website

  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    100%2
    10%1

    Lobbyists (Full time equivalent)

    2.1

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    https://easl.eu/advocacy-partners/

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    100,000€ - 199,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    100,000€ - 199,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    Cancer

    Communication activities

    EASL regularly organises high-level advocacy events on liver cancer prevention and early detection:
    e.g :
    - on 22 October in Ljubljana, on the occasion of the Slovenian presidency:https://easl.eu/news/lcam-2021/
    - On the 2of December 2021 the launch of the EASl Lancet Report on Liver Disease in Europe.
    - Event at the EU Parlement under the secretariat of the MEPs Friends of the Liver Group: https://easl.eu/eu-international-bodies-collaboration/
    - Launch of the EASL Lancet Liver Commission 2.0 in November 2023.
    - Programme called EASL Studio Policy Dialogues, educational videos with Member of the European Parliament, EU policy makers and hepatologists. https://easlcampus.eu/policy-dialogues
    - Press releases on EU votes: https://easl.eu/press-release/ncds-nov-2023/

    EASL regularly publishes Policy Statements with recommendations for policy changes in the area of alcohol, healthy food, viral hepatitis elimination, liver cancer. Two new policy statements were released in 2023. https://easl.eu/publications/easl-policy-statements/

    More information here: https://easl.eu/publications/easl-policy-statements/.

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard